Coronary disease & ACSSecondary analysis
Beta-blocker therapy and physical activity after myocardial infarction: a preplanned sub-study of the BETAMI trial
- Secondary analysis of the BETAMI randomised trial
- pre-planned sub-study
Authors' conclusion
Beta-blocker therapy did not result in a change in PA level in post-MI patients without heart failure during the 18 months follow-up.
Study context
- Population
- Patients hospitalised with myocardial infarction (MI) without HF (LVEF ≥40%)2,185 (76%) analysed
- Participants
- 2,867 patients
- Comparison
- Beta-blocker vs no beta-blocker
- Primary endpoint
- PA level: guideline-recommended PA level (≥30 minutes moderate activity ≥5 days/week) and self-reported hours/week of light to moderate and vigorous PA
- Follow-up
- baseline to 18-months
Primary result
Guideline-recommended PA level · 12-month follow-up
Odds ratio
0.97
95% CI 0.69–1.37
By group
Beta-blocker vs No beta-blocker
OR 0.97 (95% CI 0.69–1.37)
As reported in the abstract
Further findings
All-cause mortality and MACE, by baseline physical activity (PA) level (exploratory)
- No statistically significant interaction between treatment assignment and baseline PA level for recurrent clinical events
- P for interaction = 0.06
- exploratory, hypothesis-generating
Original publication
Beta-blocker therapy and physical activity after myocardial infarction: a preplanned sub-study of the BETAMI trial. Eur J Prev Cardiol. Published 11 August 2026. doi:10.1093/eurjpc/zwag412
Summarised from the published abstract; every number is checked against it